New Zealand markets close in 2 hours 50 minutes

BIIB Jun 2024 335.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.00000.0000 (0.00%)
As of 02:28PM EDT. Market open.
Full screen
Previous close3.0000
Expiry date2024-06-21
Day's range3.0000 - 3.0000
Contract rangeN/A
Open interest27
  • Zacks

    Ionis (IONS), Biogen Down on Ending Development of ALS Drug

    Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.

  • Reuters

    REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug

    Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study. Shares of Biogen and Ionis were each down nearly 2% in premarket trading. This marks another setback in the search for new treatments for ALS, a rare neurodegenerative disease that affects the voluntary control of limbs and leads to breathing trouble.

  • GlobeNewswire

    Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

    Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CAMBRIDGE, Mass. and CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) anno